Pyxis Oncology (PYXS) announced the appointment of Alex Kane, MBA, as Senior Vice President, Investor Relations & Capital Markets, effective immediately. He joins Pyxis Oncology from Guggenheim Securities, where he served as Vice President of Equity Capital Markets, advising biotechnology clients on financing strategies and equity transactions.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PYXS:
- Pyxis Oncology initiated with a Buy at Guggenheim
- Optimistic Buy Rating for Pyxis Oncology Driven by Promising MICVO Developments and Strategic Merck Collaboration
- Buy Rating for Pyxis Oncology: Promising Prospects for Micvo and Strong Financial Position
- Pyxis Oncology Reports Q2 2025 Financial Results
- Pyxis Oncology reports Q2 EPS (30c), consensus (35c)